CTOs on the Move

Volpara Health

www.volpara.com

 
Volpara Health provides an advanced AI software platform that enables a high-quality, optimized and personalized cancer screening experience. From the time a patient enters a clinic to the moment they obtain key results, the Volpara Breast Health Platform collects and analyzes information to better understand a patient`s breast cancer risk, while also objectively evaluating image quality and workflow-improvement opportunities. More than thirteen million women across 39 countries have had their breast density assessed by Volpara. The company`s software is installed in approximately 2000 leading facilities worldwide, including top cancer centers in the United States. Volpara Health`s technology has been the ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.volpara.com
  • 19000 33rd Avenue W Suite 130
    Lynnwood, WA USA 98036
  • Phone: 800.305.3865

Executives

Name Title Contact Details

Similar Companies

Granite Microsystems

Granite Microsystems is Committed to Quality and Conformance. As part of our commitment to safety and durability, Granite Microsystems' solutions conform to standard UL and CUL safety requirements. Testing is performed to ensure that appropriate products

Beckman Coulter Genomics

Beckman Coulter Genomics is a Beverly, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Dearborn County Hospital

Dearborn County Hospital is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Dearborn County Hospital is based in Lawrenceburg, IN. You can find more information on Dearborn County Hospital at www.dch.org

Mount St Joseph

Mount St Joseph is a Waterville, ME-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Versartis

Versartis, Inc. (NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. The company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. Versartis` mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. Versartis is well-positioned to deliver a major innovation to the global growth hormone deficiency (GHD) market with the company`s most advanced clinical candidate, somavaratan. Somavaratan is a novel, long-acting form of recombinant human growth hormone that is in global late-stage clinical trials to treat GHD in children and adults. Twice-monthly somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance/adherence and treatment outcomes.